Replies to post #1582 on OpGen Inc (CFOR)

[mick]

COVID-19 CORONAVIRUS OUTBREAK,Coronavirus Cases 125,815,Deaths:4,607
Recovered:
67,051


https://www.worldometers.info/coronavirus/

the above is truth by china ????? not.

==========================================================

Coronavirus Cases:
125,815
113,754
---------
..12,061

Deaths:
4,607
3,990
---------
...617


Recovered:
67,832
67,051
------------
......781

[mick]

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2019
Date : 03/12/2020 @ 7:30AM
Source : GlobeNewswire Inc.
Stock : OpGen Inc (OPGN)
Quote : 2.07 0.0 (0.00%) @ 7:28AM

http://ih.advfn.com/stock-market/NASDAQ/opgen-OPGN/stock-news/81974741/opgen-to-provide-business-update-and-financial-res

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Tuesday, March 24, 2020. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details
U.S. Dial-in Number: [phone]
International Dial-in Number: [phone]
Webcast: https://edge.media-server.com/mmc/p/n7dop5wx
Conference ID: 3497986

Reply Details
U.S. Dial-in Number: [phone]
International Dial-in Number: [phone]
Conference ID: 3497986
Following the conclusion of the conference call, a replay will be available through March 31, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.

About OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Our molecular diagnostics and informatics products, product candidates and services combine our Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. The Acuitas AMR Gene Panel (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures. For more information, please visit http://www.opgen.com.

OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.

OpGen Contact:
Michael Farmer
Vice President, Marketing
[phone]
[e-mail]

Press Contact:
Matthew Bretzius
FischTank Marketing and PR
[e-mail]

Investor Contacts:
Joe Green
Edison Group
[e-mail]